Avalon Investment & Advisory cut its holdings in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 17.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 193,613 shares of the company’s stock after selling 40,227 shares during the quarter. Avalon Investment & Advisory’s holdings in Takeda Pharmaceutical were worth $3,471,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Trexquant Investment LP purchased a new position in Takeda Pharmaceutical during the 2nd quarter valued at about $270,000. US Bancorp DE lifted its position in Takeda Pharmaceutical by 22.1% in the 2nd quarter. US Bancorp DE now owns 39,208 shares of the company’s stock worth $703,000 after buying an additional 7,096 shares during the last quarter. Cozad Asset Management Inc. purchased a new position in Takeda Pharmaceutical in the 2nd quarter worth approximately $182,000. Cullen Frost Bankers Inc. increased its stake in Takeda Pharmaceutical by 647.6% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 2,213 shares of the company’s stock worth $40,000 after purchasing an additional 1,917 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in Takeda Pharmaceutical in the 2nd quarter worth approximately $289,000. 3.67% of the stock is owned by hedge funds and other institutional investors.
TAK traded down $0.04 on Thursday, reaching $18.92. 35,223 shares of the stock were exchanged, compared to its average volume of 945,953. The company’s 50-day moving average price is $17.89 and its 200 day moving average price is $17.76. Takeda Pharmaceutical Co Ltd has a fifty-two week low of $12.43 and a fifty-two week high of $20.92. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.22 and a quick ratio of 0.84. The firm has a market capitalization of $59.46 billion, a PE ratio of 10.36 and a beta of 0.98.
Several equities research analysts recently weighed in on the company. Zacks Investment Research cut Takeda Pharmaceutical from a “buy” rating to a “sell” rating in a research note on Friday, August 7th. ValuEngine raised Takeda Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, May 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $23.50.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
See Also: Monthly Dividend Stocks
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.